1. Home
  2. IMRX
  3. IMRX News

Latest Immuneering Corporation (IMRX) News on November 15, 2024

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

a day ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
IMRX

Zacks

a month ago

IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug

IMRX

MT Newswires

a month ago

Immuneering Says Potential Pancreatic Cancer Treatment Gets FDA Orphan Drug Designation

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
IMRX

GlobeNewswire

a month ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation
IMRX

Simply Wall St.

a month ago

Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
IMRX

Zacks

2 months ago

IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study

IMRX

MT Newswires

2 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday

Why Is Nanocap Immuneering Stock Trading Higher On Friday?
IMRX

Benzinga

2 months ago

Why Is Nanocap Immuneering Stock Trading Higher On Friday?

IMRX

MT Newswires

2 months ago

Top Premarket Gainers

IMRX

MT Newswires

2 months ago

Chardan Raises Price Target on Immuneering to $13 From $12, Maintains Buy Rating

IMRX

MT Newswires

2 months ago

Update: Immuneering Shares Surge Premarket as 'Positive' Data Seen in Phase 2a Pancreatic Cancer Trial

IMRX

MT Newswires

2 months ago

Immuneering Shares Surge After 'Positive' Data in Phase 2a Pancreatic Cancer Trial

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
IMRX

GlobeNewswire

2 months ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
IMRX

GlobeNewswire

3 months ago

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock
IMRX

Simply Wall St.

3 months ago

Favourable Signals For Immuneering: Numerous Insiders Acquired Stock

IMRX

MT Newswires

3 months ago

Chardan Adjusts Immuneering Price Target to $16 From $12, Maintains Buy Rating

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

3 months ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
IMRX

GlobeNewswire

3 months ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/18/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/17/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/14/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/13/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/12/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/11/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/10/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/07/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/06/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/05/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/04/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 06/03/2024

IMRX

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 05/31/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/30/2024

Immuneering to Present at the Jefferies Global Healthcare Conference
IMRX

GlobeNewswire

6 months ago

Immuneering to Present at the Jefferies Global Healthcare Conference

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/29/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/28/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/24/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/23/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/22/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/21/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/20/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/17/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/16/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/15/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/14/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/13/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/10/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/09/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/08/2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

6 months ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully
IMRX

Simply Wall St.

6 months ago

We Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth Carefully

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/07/2024

Immuneering Recognizes Melanoma Awareness Month
IMRX

GlobeNewswire

6 months ago

Immuneering Recognizes Melanoma Awareness Month

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/06/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/03/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/02/2024

IMRX

Argus Research

6 months ago

Daily – Vickers Top Insider Picks for 05/01/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/30/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/29/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/26/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/25/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/24/2024

IMRX

Argus Research

7 months ago

Daily – Vickers Top Insider Picks for 04/23/2024

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
IMRX

GlobeNewswire

7 months ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
IMRX

GlobeNewswire

7 months ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
IMRX

GlobeNewswire

8 months ago

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

Immuneering Director Acquires 7.5% More Stock
IMRX

Simply Wall St.

8 months ago

Immuneering Director Acquires 7.5% More Stock

Immuneering (IMRX) Plummets 71% in One Week: Here's Why
IMRX

Zacks

8 months ago

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
IMRX

GlobeNewswire

8 months ago

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
IMRX

GlobeNewswire

8 months ago

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
IMRX

GlobeNewswire

8 months ago

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
IMRX

GlobeNewswire

8 months ago

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

Immuneering to Participate in the Cowen 44th Annual Health Care Conference
IMRX

GlobeNewswire

8 months ago

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

IMRX

GuruFocus.com

8 months ago

Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
IMRX

GlobeNewswire

8 months ago

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
IMRX

GlobeNewswire

9 months ago

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
IMRX

InvestorPlace

9 months ago

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Immuneering Announces Participation in February Investor Conferences
IMRX

GlobeNewswire

9 months ago

Immuneering Announces Participation in February Investor Conferences

IMRX

Thomson Reuters StreetEvents

10 months ago

Q2 2024 LSI Industries Inc Earnings Call

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...
IMRX

GuruFocus.com

10 months ago

LSI Industries Inc. (LYTS) Reports Q2 Fiscal 2024 Results: Net Income Dips Slightly Amidst ...

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results
IMRX

Simply Wall St.

10 months ago

Analysts Are Updating Their Citizens & Northern Corporation (NASDAQ:CZNC) Estimates After Its Full-Year Results

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure
IMRX

Business Wire

10 months ago

ChargePoint Becomes One of the First EV Charging Providers to Receive FedRAMP Approval for the Implementation of Federal EV Charging Infrastructure

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
IMRX

Zacks

10 months ago

Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx

Pinstripes Holdings, Inc. Rings the NYSE Opening Bell Today and Reports Preliminary Unaudited Fiscal 2024 Third Quarter Sales Results
IMRX

Business Wire

10 months ago

Pinstripes Holdings, Inc. Rings the NYSE Opening Bell Today and Reports Preliminary Unaudited Fiscal 2024 Third Quarter Sales Results

Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
IMRX

GlobeNewswire

10 months ago

Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases

Forum Energy Technologies to Present at the Sidoti Virtual Investor Conference
IMRX

Business Wire

10 months ago

Forum Energy Technologies to Present at the Sidoti Virtual Investor Conference

Ceva and THX Ltd. Partner to Bring Premium Spatial Audio to Hearables, Consumer and Mobile Products
IMRX

PR Newswire

10 months ago

Ceva and THX Ltd. Partner to Bring Premium Spatial Audio to Hearables, Consumer and Mobile Products

With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors
IMRX

Simply Wall St.

10 months ago

With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors

Rimini Street (NASDAQ:RMNI) shareholders have endured a 35% loss from investing in the stock five years ago
IMRX

Simply Wall St.

a year ago

Rimini Street (NASDAQ:RMNI) shareholders have endured a 35% loss from investing in the stock five years ago

While institutions own 21% of Perfect Corp. (NYSE:PERF), public companies are its largest shareholders with 41% ownership
IMRX

Simply Wall St.

a year ago

While institutions own 21% of Perfect Corp. (NYSE:PERF), public companies are its largest shareholders with 41% ownership

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
IMRX

GlobeNewswire

a year ago

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
IMRX

GlobeNewswire

a year ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Insider Sell Alert: COO Jason Dale Sells 40,000 Shares of Vital Farms Inc (VITL)
IMRX

GuruFocus.com

a year ago

Insider Sell Alert: COO Jason Dale Sells 40,000 Shares of Vital Farms Inc (VITL)

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Fourth Quarter Common Stock Distribution of $0.1270 Per Share
IMRX

GlobeNewswire

a year ago

Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Fourth Quarter Common Stock Distribution of $0.1270 Per Share

15 US States with the Most Debt Per Capita
IMRX

Insider Monkey

a year ago

15 US States with the Most Debt Per Capita

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
IMRX

Simply Wall St.

a year ago

Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
IMRX

GlobeNewswire

a year ago

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

ARIS MINING INCREASES SEGOVIA GOLD MINERAL RESERVES BY +75% TO 1.3 MOZ AND ANNOUNCES PLANT EXPANSION TO INCREASE PRODUCTION RATE
IMRX

CNW Group

a year ago

ARIS MINING INCREASES SEGOVIA GOLD MINERAL RESERVES BY +75% TO 1.3 MOZ AND ANNOUNCES PLANT EXPANSION TO INCREASE PRODUCTION RATE

PureCycle Releases Favorable Life Cycle Assessment Results for European Facility
IMRX

ACCESSWIRE

a year ago

PureCycle Releases Favorable Life Cycle Assessment Results for European Facility

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
IMRX

Business Wire

a year ago

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
IMRX

GlobeNewswire

a year ago

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

Share on Social Networks: